Plain-English translation of NCT04401982 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing how netarsudil (sold as Rhopressa), latanoprost, and a combination of both medications affect blood flow in the small blood vessels around your eye. Researchers want to understand whether adding netarsudil to latanoprost improves blood flow better than latanoprost alone, which could explain why the combination works so well at lowering eye pressure.
Glaucoma causes blindness by damaging the eye when pressure builds up inside it. While doctors know that lowering this pressure slows the disease, they don't fully understand how different medications work on the tiny blood vessels that drain fluid from the eye. This study will help fill that gap and may lead to better ways of measuring whether treatments are working.
You likely qualify if…
You likely don't qualify if…
You will receive eye drops containing the study medication and visit the clinic for several appointments where researchers will take special imaging pictures of the blood vessels in your eye to measure how well blood is flowing. The imaging is noninvasive and safe—it uses harmless light to see the blood vessels without needing injections or surgery. The study will help doctors understand which medication combination works best for your eye health.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States